Unknown

Dataset Information

0

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

ABSTRACT: Immunotherapy has the potential to support and expand the body's own armamentarium of immune effector functions, which have been circumvented during malignant transformation and establishment of cancer and is presently considered to be the most promising treatment option for cancer patients. Recombinant antibody technologies have led to a multitude of novel antibody formats, which are in clinical development and hold great promise for future therapies. Among these formats, bispecific antibodies are extremely versatile due to their high efficacy to recruit and activate anti-tumoral immune effector cells, their excellent safety profile, and the opportunity for use in combination with cellular therapies. This review article summarizes the latest developments in cancer immunotherapy using immuno-engagers for recruiting T cells and NK cells to the tumor site. In addition to antibody formats, malignant cell targets, and immune cell targets, opportunities for combination therapies, including check point inhibitors, cytokines and adoptive transfer of immune cells, will be summarized and discussed.

SUBMITTER: Koch J 

PROVIDER: S-EPMC5649249 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

Koch Joachim J   Tesar Michael M  

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 20170911 5

Immunotherapy has the potential to support and expand the body's own armamentarium of immune effector functions, which have been circumvented during malignant transformation and establishment of cancer and is presently considered to be the most promising treatment option for cancer patients. Recombinant antibody technologies have led to a multitude of novel antibody formats, which are in clinical development and hold great promise for future therapies. Among these formats, bispecific antibodies  ...[more]

Similar Datasets

Unknown Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
| S-EPMC4074851 | biostudies-literature
Unknown Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer.
| S-EPMC8119359 | biostudies-literature
Unknown Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes.
| S-EPMC4834990 | biostudies-literature
Unknown SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma.
| S-EPMC5843685 | biostudies-literature
Unknown Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy.
| S-EPMC5353927 | biostudies-literature
Unknown Bispecific antibodies in cancer immunotherapy.
| S-EPMC5933537 | biostudies-literature
Unknown Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.
| S-EPMC5101144 | biostudies-literature
Unknown Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
| S-EPMC7760325 | biostudies-literature
Unknown Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
| S-EPMC3521877 | biostudies-literature
Proteomics Doxycycline treated cytotoxic T lymphocytes
2022-06-09 | PXD026948 | Pride